Not long ago, the CDK4/6 inhibitor SHR6390 developed by Jiangsu Hengrui has been submitted to the domestic NDA for breast cancer; and one month ago, this product was also included in the breakthrough treatment program of CDE.It is used to treat HR-positive/HER2-negative recurrent or metastatic breast cancer that has progressed after endocrine therapy combined with fulvestrant.

SHR6390 is a new class 1 chemical drug independently developed by Hengrui Medicine. It is an oral, high-efficiency and selective small molecule CDK4/6 inhibitor. It can block the CDK4/6-Rb signaling pathway and induce cell G1 blockade. Hysteresis and selectively inhibits the proliferation of tumor cells with high Rb expression. Therefore, it plays a decisive role in blocking the process of cells from G1 phase to S phase, thereby inhibiting the proliferation of tumor cells and achieving anti-tumor effects.

Currently, Hengrui Medicine is carrying out a number of clinical studies on SHR6390 in HR-positive breast cancer, involving the treatment of breast cancer at different stages of disease development. SHR6390 tablets have been included in the priority review and are expected to be approved quickly and become a new treatment option for breast cancer patients in the future.